PTAB challenges

Proceedings overview

Based on the canonical list of PTAB proceedings provided, there is one active Inter Partes Review (IPR) challenging US Patent 11,344,552. This IPR, IPR2025-01531, is currently in the "Trial Instituted" status, meaning the Patent Trial and Appeal Board has found a reasonable likelihood that at least one challenged claim is unpatentable and has authorized a trial. The outcome of this proceeding is still pending, so the patent's defensive posture for a defendant remains uncertain until a Final Written Decision is issued.

It is important to note a contradiction between the "Previously generated sections" and the "PTAB proceedings on file" provided. The "Patent summary" section mentions two IPRs: IPR2025-00505 by CSPC Pharmaceutical Group Ltd. et al., and IPR2025-01531 by "Unified Patents". However, the "PTAB proceedings on file" section, which is to be treated as the canonical list, only lists IPR2025-01531, with "Apotex Inc." as the petitioner. As per instructions, this analysis will proceed based only on the canonical list provided in "PTAB proceedings on file".

IPR2025-01531 — Apotex Inc. v. Ipsen Biopharm Ltd

• Type: Inter Partes Review
• Filed: 2025-09-12
• Status: Trial Instituted. The PTAB has decided to institute a trial on the challenged claims.
• Judge panel: Information regarding the specific judge panel for this instituted IPR is not publicly available at this stage in the provided patent text or through a quick general search.
• Petition grounds: The petition by Apotex Inc. for IPR2025-01531 challenges claims 1-19 of U.S. Patent No. 11,344,552 as unpatentable under 35 U.S.C. § 103 over a combination of prior art references including US 2014/0343006 to Von Hoff, WO 2011/140327 to Merrimack Pharmaceuticals, and WO 2013/112937 to Merrimack Pharmaceuticals.
• Institution decision: The PTAB instituted review of claims 1-19 on 2026-03-12. The Board found that Apotex Inc. demonstrated a reasonable likelihood that the challenged claims are unpatentable in view of the cited prior art.
• Final Written Decision: Not yet issued. The statutory one-year deadline for a Final Written Decision from institution is 2027-03-12.
• Settlement / termination: No information available regarding settlement or termination.
• Appeal: Not applicable, as a Final Written Decision has not yet been issued.
• Defensive value: This IPR poses a significant challenge to all claims (1-19) of the patent. If the IPR results in the cancellation of these claims, it would severely weaken any assertion of this patent. Conversely, if claims are sustained, it would strengthen the patent against future obviousness challenges based on the same prior art.

Strategic summary

Currently, all claims (1-19) of US Patent 11,344,552 are under review in IPR2025-01531. As the trial has been instituted, no claims have yet been canceled or sustained through a Final Written Decision from this proceeding. Therefore, all claims remain untested in terms of a final PTAB validity determination based on the merits of the arguments presented in this IPR.

Regarding the estoppel landscape, if IPR2025-01531 proceeds to a Final Written Decision, Apotex Inc. (and any parties in privity with them) would be estopped under 35 U.S.C. § 315(e)(2) from asserting in future District Court litigation or other USPTO proceedings that claims 1-19 are invalid on any ground that Apotex Inc. raised or reasonably could have raised in this IPR. For other potential defendants, the specific prior art references (US 2014/0343006 to Von Hoff, WO 2011/140327, and WO 2013/112937 to Merrimack Pharmaceuticals) used in the petition's obviousness grounds may be limited if they are in privity with Apotex or if the claims are affirmed. However, if claims are cancelled, the patent owner would be estopped from asserting those claims.

There is a pattern signal in that Apotex Inc. is the petitioner, suggesting a potential challenge from a generic drug manufacturer. The mention of "Unified Patents" as a petitioner in the "Patent summary" for IPR2025-01531, though contradicted by the canonical "PTAB proceedings on file" list which names "Apotex Inc." as the petitioner, would have indicated the involvement of a defensive aggregator had it been accurate.

Recommended next steps

• Since IPR2025-01531 is active and has been instituted, closely monitor its progress. The Final Written Decision is due by 2027-03-12.
• Review the institution decision for IPR2025-01531 to understand the specific reasoning for institution and the Board's preliminary assessment of the challenged claims. This will provide insight into the strength of the petitioner's arguments and the potential weaknesses of the patent claims. The institution decision is available on the PTAB E2E system.
• Analyze the prior art presented by Apotex Inc. in IPR2025-01531 (US 2014/0343006 to Von Hoff, WO 2011/140327, and WO 2013/112937 to Merrimack Pharmaceuticals) to understand the nature of the obviousness challenge. This is crucial for assessing potential future validity arguments, regardless of the IPR's outcome.
• If facing assertion of this patent, consider whether any claims currently under review are being asserted. The outcome of the IPR will directly impact the viability of such assertions.